着丝粒蛋白N在乳腺癌中的表达、免疫调控功能及临床预后价值
该研究基于TCGA等数据库及17例本地乳腺癌组织,分析CENPN在浸润性乳腺癌中的表达、预后及免疫调控作用。CENPN在癌组织中高表达,与不良生存及免疫细胞浸润相关;敲降CENPN可抑制MCF-7细胞增殖迁移并增强化疗敏感性。CENPN可能是乳腺癌预后标志物和免疫治疗靶点。
要点
- CENPN在乳腺癌组织中高表达,与总生存期、无复发生存期等不良预后相关。
- CENPN表达与肿瘤突变负荷负相关,并与多种免疫细胞浸润及免疫检查点基因相关。
- 敲降CENPN抑制MCF-7细胞增殖迁移,并增强5-氟尿嘧啶和吉西他滨的敏感性。
核心结论
- CENPN可作为预测乳腺癌预后的潜在生物标志物,也是乳腺癌免疫治疗的潜在靶点。
研究设计与样本
- 基于TCGA、HPA、cBioPortal、GEPIA 2.0、STRING和TIMER 2.0数据库的生物信息学分析。
- 利用2022年1月至2023年4月在烟台市烟台山医院行手术治疗的17例乳腺癌患者的癌与癌旁组织进行验证。
- 体外实验采用CCK-8法和划痕实验检测CENPN对MCF-7细胞增殖和迁移的影响。
主要发现
- TCGA数据库显示乳腺癌组织中CENPN表达高于癌旁正常组织(P<0.05)。
- 17例乳腺癌组织CENPN阳性率为82.4%,显著高于癌旁组织的5.9%(P<0.001)。
- CENPN高表达患者总生存期(HR=1.39,P<0.001)、无复发生存期(HR=1.31,P<0.001)、进展后生存期(HR=1.28,P=0.036)和无远处转移生存期(HR=1.6,P<0.001)较差。
- CENPN表达与肿瘤突变负荷呈负相关(r=-0.196,P<0.001),与20个常见免疫检查点基因中的5个正相关、15个负相关。
- 敲降CENPN显著抑制MCF-7细胞增殖和迁移,并增强其对5-氟尿嘧啶和吉西他滨的化疗敏感性。
关键数值与推荐
- CENPN高表达与总生存期HR=1.39(P<0.001)、无复发生存期HR=1.31(P<0.001)、进展后生存期HR=1.28(P=0.036)、无远处转移生存期HR=1.6(P<0.001)相关。
- CENPN表达与肿瘤突变负荷负相关(r=-0.196,P<0.001)。
- CENPN在乳腺癌组织阳性率82.4% vs 癌旁5.9%(P<0.001)。
临床怎么用
- CENPN高表达可能提示乳腺癌患者预后较差,可作为预后评估的潜在参考指标。
- CENPN表达与免疫细胞浸润及免疫检查点基因相关,可能辅助预测免疫治疗反应。
- 敲降CENPN可增强MCF-7细胞对5-氟尿嘧啶和吉西他滨的敏感性,提示其作为化疗增敏靶点的潜力。
局限性
- 本地验证队列样本量仅17例,结果需更大样本验证。
- 研究以生物信息学分析和体外细胞实验为主,缺乏体内实验及临床治疗队列验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the expression profile of Centromere Protein N (CENPN) in invasive breast cancer (BRCA), evaluate its prognostic significance, and assess its involvement in immune regulation. Methods: The expression, prognostic value, and correlation with tumor immunogenicity of CENPN in BRCA tissues were analyzed based on The Cancer Genome Atlas (TCGA) database. Verification was conducted using cancerous and adjacent normal tissues from BRCA patients who underwent surgical treatment at Yantai Mountain Hospital between January 2022 and April 2023. CENPN expression in various immune cells in the blood was examined using the Human Protein Atlas (HPA) database. Genetic alterations of CENPN in breast cancer tissues were analyzed via the cBioPortal database. CENPN-related genes were screened using the GEPIA 2.0 database, and the interaction network between CENPN and similar genes was visualized with the STRING database. Gene Ontology (GO) enrichment analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, and Gene Set Enrichment Analysis (GSEA) were employed to explore the potential biological functions of CENPN. The correlation between CENPN expression and immune cell infiltration, as well as immune cell markers in BRCA tissues, was assessed using the TIMER 2.0 database. The effect of CENPN on the proliferation ability of breast cancer MCF-7 cells was detected by the CCK-8 assay, and its impact on the migration ability of MCF-7 cells was evaluated by a wound healing assay. Results: Analysis of TCGA database data revealed that CENPN expression was significantly higher in BRCA tissues compared to adjacent normal tissues (P<0.05). Validation in our institutional cohort demonstrated a significantly higher positivity rate for CENPN in the 17 breast cancer tissues (82.4%) than in the paired paracancerous tissues (5.9%, P<0.001). According to the HPA database, elevated CENPN expression was observed in T-reg cells, naïve B cells, and myeloid dendritic cells. Kaplan-Meier survival analysis indicated that patients with high CENPN expression had poorer overall survival (HR=1.39, P<0.001), recurrence-free survival (HR=1.31, P<0.001), post-progression survival (HR=1.28, P=0.036), and distant metastasis-free survival (HR=1.6, P<0.001). Correlation analysis revealed a negative association between CENPN expression and tumor mutational burden in BRCA patients (r=-0.196, P<0.001). Furthermore, CENPN expression was positively correlated with 5 out of 20 common immune checkpoint genes and negatively correlated with the remaining 15, suggesting its potential for predicting immunotherapy response. Analysis via the cBioPortal database showed that invasive lobular breast carcinoma had the highest CENPN alteration frequency, with amplification being the most common alteration in BRCA. Invasive mixed mucinous breast carcinoma exhibited the highest mutation frequency, and a key missense mutation (K329N) was identified as a potential driver in BRCA.GO enrichment analysis demonstrated that CENPN-related genes were primarily involved in cell cycle, DNA metabolic processes, cell division, nuclear lumen, chromosomes, nucleoplasm, and functions related to ATP, nucleotide, and small molecule binding. KEGG pathway analysis indicated significant enrichment in DNA replication, cellular senescence, mismatch repair, homologous recombination, p53 signaling pathway, and FOXO signaling pathway. Correlation analysis using the TIMER 2.0 database established associations between CENPN expression and the infiltration levels of B cells, CD4+ T cells, CD8+ T cells, macrophages, neutrophils, and dendritic cells in BRCA. Positive correlations were also found with markers for CD8+ T cells, B cells, T cells, and T-cell exhaustion.CCK-8 assay and wound healing experiments confirmed that CENPN knockdown significantly suppressed malignant phenotypes, including proliferation and migration, in MCF-7 cells. Additionally, CENPN knockdown was found to enhance the chemosensitivity of MCF-7 cells to the anti-tumor agents 5-fluorouracil and gemcitabine. Conclusion: CENPN serves as a potential prognostic biomarker and a novel target for immunotherapy in BRCA. 目的: 探讨着丝粒蛋白N(CENPN)在浸润性乳腺癌(BRCA)中的表达特征、预后价值及在免疫调控中的作用。 方法: 基于癌症基因组图谱(TCGA)数据库分析BRCA组织中CENPN的表达、预后价值及与BRCA肿瘤免疫原性的相关性,利用2022年1月至2023年4月在烟台市烟台山医院行手术治疗的17例BRCA患者的癌组织及癌旁正常组织进行验证。基于人类蛋白质图谱(HPA)数据库分析CENPN在血液各种免疫细胞中的表达。通过cBioPortal数据库分析乳腺癌组织中的CENPN基因变异情况。通过基因表达谱数据动态分析2.0数据库筛选CENPN相关基因,并通过相互作用基因/蛋白检索工具网站可视化CENPN与相关基因的相互作用网络,采用基因本体论(GO)富集分析、京都基因和基因组百科全书(KEGG)分析以及基因集富集分析探索CENPN可能的生物学功能。利用肿瘤免疫浸润估算资源(TIMER)数据库2.0评估CENPN表达与BRCA组织中免疫细胞浸润及免疫细胞标志物之间的相关性。采用CCK-8法检测CENPN对乳腺癌MCF-7细胞增殖能力的影响,采用划痕实验评估CENPN对MCF-7细胞迁移能力的影响。 结果: TCGA数据库资料显示,BRCA组织中CENPN的表达高于癌旁正常组织(P<0.05)。自有的17例乳腺癌组织CENPN阳性率为82.4%,显著高于癌旁组织(5.9%,P<0.001)。HPA数据库资料显示,CENPN在T-reg细胞、初始B细胞以及髓样树突状细胞中表达增强。Kaplan-Meier生存分析显示,CENPN高表达患者的总生存期(HR=1.39,P<0.001)、无复发生存期(HR=1.31,P<0.001)、进展后生存期(HR=1.28,P=0.036)和无远处转移生存期(HR=1.6,P<0.001)较差。相关性分析显示,CENPN表达与BRCA患者的肿瘤突变负荷呈负相关(r=-0.196,P<0.001),与20个常见的免疫检查点基因中的5个呈正相关,15个呈负相关,具有预测免疫治疗有效性的潜力。cBioPortal数据库分析显示,乳腺浸润性小叶癌中CENPN变异发生率最高,BRCA中CENPN的扩增频率最高,乳腺浸润性混合性黏液癌中突变频率最高,CENPN区错义突变点位位于K329N,其可能是BRCA的推定驱动因素。GO功能富集分析显示,CENPN相关基因主要与细胞周期、DNA代谢过程、细胞分裂、核腔、染色体、核浆、三磷酸腺苷结合、核苷酸结合以及小分子结合等功能有关。KEGG通路富集分析显示,CENPN相关基因主要富集在DNA复制、细胞衰老、错配修复、同源重组、p53及叉头框蛋白O等信号通路中。通过TIMER 2.0数据库的相关分析显示,CENPN表达与BRCA中的B细胞、CD4+ T细胞、CD8+ T细胞、巨噬细胞、中性粒细胞及树突状细胞之间存在相关性,且与CD8+ T细胞标志物、B细胞标志物、T细胞标志物和T细胞衰竭标志物呈正相关。CCK-8法和划痕实验结果显示,敲降CENPN能够显著抑制MCF-7细胞的增殖和迁移等恶性特征,且能够进一步增强MCF-7细胞对抗肿瘤药物5-氟尿嘧啶和吉西他滨的化疗敏感性。 结论: CENPN可作为预测乳BRCA预后的潜在生物标志物,也是BRCA免疫治疗的潜在靶点。.
引用
- Tian R, Ni GF, Fan QD, et al. [Expression profile, immunoregulatory function, and clinical prognostic value of CENPN in breast cancer]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 42595550. doi:10.3760/cma.j.cn112152-20250515-00224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。